Evidence map›Paper›PMID 40661990›Full record

ArticleTherapeutic advances in medical oncology2025

HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

Mingjun Rui, Yingcheng Wang, Qiran Wei, Joyce H S You

Abstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mingjun RuiSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.ORCID https://orcid.org/0000-0001-8649-6454
Yingcheng WangSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.ORCID https://orcid.org/0000-0002-1784-4504
Qiran WeiSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.ORCID https://orcid.org/0000-0002-0261-6381
Joyce H S YouSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 8/F, Lo Kwee-Seong Integrated Biomedical Sciences Building, Shatin, Hong Kong SAR, China.ORCID https://orcid.org/0000-0002-5763-7403

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Talazoparib plus enzalutamide showed significant improvement of progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in homologous recombination repair (HRR) genes. Objectives: This study aimed to evaluate the cost-effectiveness of HRR status-guided use of talazoparib plus enzalutamide in patients with mCRPC from the U.S. payer perspective. Design: A partitioned survival model was used to simulate outcomes of a hypothetical cohort of mCRPC patients. Methods: Three treatment strategies were evaluated: (1) talazoparib plus enzalutamide for HRR-deficient patients and enzalutamide for non-HRR-deficient patients (HRR-guided talazoparib plus enzalutamide), (2) talazoparib plus enzalutamide for patients with or without HRR deficiency (empirical talazoparib plus enzalutamide), and (3) enzalutamide for patients with or without HRR deficiency (empirical enzalutamide). Primary outcomes were direct medical costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost per QALY gained (incremental cost-effectiveness ratio, ICER). Sensitivity analyses were performed to examine the robustness of model results. Results: In base-case analysis, the empirical enzalutamide strategy had the lowest cost and QALYs gained (US$752,383; 2.4764 QALYs), followed by HRR-guided talazoparib plus enzalutamide (US$878,517; 2.6490 QALYs), and empirical talazoparib plus enzalutamide (US$1,201,221; 2.8418 QALYs). The ICER of the HRR-guided talazoparib plus enzalutamide group (vs empirical enzalutamide) was US$730,671 per QALY gained, and the ICER of empirical talazoparib plus enzalutamide (vs HRR-guided talazoparib plus enzalutamide) was US$1,673,457 per QALY gained. Both ICERs of the HRR-guided strategy and empirical combination therapy were higher than the willingness-to-pay threshold (US$100,000 per QALY) and were not accepted as cost-effective. Sensitivity analyses found drug costs of talazoparib and enzalutamide to be the key influential factors on the cost-effectiveness of HRR-guided therapy. Conclusion: HRR-guided talazoparib plus enzalutamide does not appear to be cost-effective for mCRPC patients from the U.S. payer perspective.

Indexed as

cost-effectiveness analysisenzalutamidehealth services researchhomologous recombination repairmetastatic castration-resistant prostate cancertalazoparib

Identifiers

PMID40661990
PMCPMC12256737

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.